Increased serum levels of endostatin in patients with idiopathic pulmonary fibrosis
Increased serum levels of endostatin in patients with idiopathic pulmonary fibrosis
复制标题
DOI：
10.1002/jcla.20069
复制
发表时间：
2005-01-01
影响因子：
2.7
通讯作者：
Sekizawa, K
中科院分区：
文献类型：
--
作者：
Sumi, M;Satoh, H;Sekizawa, K
内皮抑素是一种血管生成抑制剂，是XVIII型胶原蛋白的内源性蛋白水解片段。恶性肿瘤患者血清内皮抑素水平已被广泛研究。最近，在伴有肺纤维化的系统性硬化症患者中观察到血清内皮抑素水平升高。为了确定特发性肺纤维化（IPF）患者血清内皮抑素是否升高，我们使用ELISA试剂盒检测了69例良性呼吸系统疾病患者的血清内皮抑素水平。这些患者的血清内皮抑素水平中位数为50.8 pg/mL。7/11例（63.6%）胶原病相关性肺纤维化（CDPF）患者和19/24例（79.2%）IPF患者的血清内皮抑素水平高于69例患者的中位数水平。IPF组与CDPF组血清内皮抑素水平比较差异无统计学意义（P=0.7898）。24例IPF患者的血清内皮抑素水平显著高于34例非IPF和CDPF呼吸系统疾病患者（P=0.0001）。在IPF患者中观察到血清内皮抑制素水平升高。虽然机制尚不清楚，但血清内皮抑素水平升高可能与肺纤维化过程有关。
Endostatin is an angiogenesis inhibitor that is an endogenously produced proteolytic fragment of type XVIII collagen. Serum levels of endostatin have been studied extensively in patients with malignant diseases. Recently, elevated serum endostatin levels were observed in patients with systemic sclerosis accompanying pulmonary fibrosis. To determine whether elevated serum endostatin can be observed in patients with idiopathic pulmonary fibrosis (IPF), we measured serum levels of endostatin in 69 patients with benign respiratory disease using an ELISA kit. The median of the serum endostatin levels in these patients was 50.8 pg/mL. Seven of 11 patients (63.6%) with collagen disease-associated pulmonary fibrosis (CDPF), and 19 of 24 patients (79.2%) with IPF had higher serum endostatin levels than the median level of the 69 patients. There was no statistical difference in serum endostatin levels between the patients with IPF and those with CDPF (P=0.7898). Serum endostatin levels in 24 patients with IPF were significantly higher than those in 34 patients with respiratory diseases other than IPF and CDPF (P=0.0001). Elevated serum levels of endostatin were observed in patients with IPF. Although the mechanisms are unclear, elevated serum levels of endostatin may be related to the fibrosing process in the lung.